

Prevalence and Determinants of Overweight; Obesity; and Weight Gain among Young Women in Costa Rica

Bianka Bonilla^{1*}, Romain Fantin¹, Carolina Porras¹, Juan Carlos Vanegas¹, Juan José Romero-Zúñiga², Aimée R Kreimer³, Allan Hildesheim¹ and Rolando Herrero¹

¹Agencia Costarricense de Investigaciones Biomédicas-Fundación Inciensa (ACIB-FUNIN). San José, Costa Rica

²Programa de Investigación en Medicina Poblacional, Escuela de Medicina Veterinaria, Universidad Nacional (UNA). Heredia, Costa Rica

³Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland

*Corresponding Author

Bianka Bonilla, Agencia Costarricense de Investigaciones Biomédicas-Fundación Inciensa (ACIB-FUNIN). San José, Costa Rica, Tel: (506) 86642192, E-mail: biankabc08@gmail.com

Citation

Bianka Bonilla, Romain Fantin, Carolina Porras, Juan Carlos Vanegas, Juan José Romero-Zúñiga (2025) Prevalence and Determinants of Overweight; Obesity; and Weight Gain among Young Women in Costa Rica. J Obes Comp 1: 1-24

Publication Dates

Received date: November 18, 2025

Accepted date: December 05, 2025

Published date: December 20, 2025

Abstract

Background: Obesity is a critical public health issue worldwide, with Latin America among the most affected regions. Early adulthood is a key period to prevent excess weight gain, particularly in women.

Methods: We analyzed data from 7,465 women aged 18–25 in the Costa Rica HPV Vaccine Trial. Body Mass Index (BMI) classified overweight (25–29.9) and obesity (≥ 30). Prevalence was assessed among the same women at baseline (2004/2005) and follow-up (2010/2011). Logistic regression identified determinants of overweight/obesity and $\geq 20\%$ weight gain.

Results: Prevalence of overweight/obesity increased from 35% to 56% over five years. In adjusted models, older age, lower education, early menarche (≤ 10 years), irregular periods, pregnancies, injectable contraceptive use and smoking increased risk, while being single was protective. Coastal regions had higher prevalence than mountainous areas. Weight gain was associated with early menarche, new pregnancies, oral contraceptive use and marriage, whereas pregnancies before enrollment lowered risk.

Conclusions: Rapid increases in overweight/obesity among young women underscore the influence of social and reproductive factors. Interventions addressing educational and geographic differences are needed. Further studies on diet and physical activity will strengthen preven-

tion and guide public health policy.

Keywords: Epidemiology, Observational Study, Sociodemographic Factors, Reproductive Health, Body Mass Index, Inequities.

Introduction

Obesity is a complex, global health crisis characterized by excessive body fat accumulation, that affects individuals with a BMI ≥ 30 and is associated with type 2 diabetes, heart disease, 13 types of cancer [1], anemia [2], aging [3], increased bone fragility [4], infections, and alterations of the immune system [5]. Furthermore, obesity can affect fertility and influence the quality of life, potentially hampering sleep and mobility [6]. Beyond its direct health implications, obesity is associated with a range of economic consequences, including increased healthcare expenditures and potential productivity losses [7, 8].

The prevalence of overweight and obesity has reached epidemic proportions worldwide. Globally, in 2022, 43% of adults were classified as people with overweight, and approximately 16% as people with obesity [9]. In Latin America and the Caribbean, 63% of adults are people with overweight and 27% are people with obesity [10]. Costa Rica is not exempt from this trend: 63% of adult men and 65% of adult women aged 18 and older are classified as people with overweight [11]. Notably, obesity is more prevalent among Costa Rican women, affecting 34% compared to 25% of men [11]. According to statistics of the Costa Rican Social Security Fund (Caja Costarricense de Seguro Social, CCSS), the Greater Metropolitan Area around the capital exhibits the highest rates of overweight and obesity [12].

The early adult years (18-25) are considered a critical life stage for preventing and controlling weight gain [13]. During this period, individuals undergo significant physical, emotional, and social changes related to education, employment, and personal life, which can create challenges for maintaining a healthy weight [13]. Also, young adults often face a lack of time [14], motivation, and social support [15], which makes it difficult to maintain healthy behaviors. Academic and occupational changes bring challenges that can influence dietary behaviors and food choices. As a result, young adults often adopt less healthy eating patterns and daily activities to main-

tain a healthy weight [13].

During this critical period of life, women are more likely than men to drop out of sports [16] and interrupt athletic training [17]. Motherhood often reduces the time women dedicate to self-care, including physical activity [14, 18].

Previous research in Costa Rica has examined obesity in the general population [19, 20], but there is limited data on weight gain among young women.

To address this gap, we aimed to assess the prevalence and determinants of overweight and obesity, as well as to evaluate the determinants associated with weight gain in Costa Rican young women between two time points: 2004–2005 and 2010–2011.

Methods

Study Population and Data Collection

Data are from the “Phase III efficacy study of the Human Papillomavirus (HPV) 16/18 vaccine for the prevention of advanced cervical neoplasia associated with HPV 16 or HPV 18”, also known as the Costa Rica Vaccine Trial (CVT). It was a community-based, double-blind, controlled, randomized clinical trial conducted on healthy young adult women from the provinces of Guanacaste and Puntarenas in Costa Rica, recruited from June 2004 to December 2005.

Study methods have been reported [21, 22]. Briefly, CVT enrolled 7465 healthy women aged 18 to 25 years who resided in Guanacaste Province or selected areas of Puntarenas during 2004–2005. Women were included if they were born between July 1978 and November 1987, were able to speak and understand Spanish, appeared mentally competent, and were willing to use contraception. Women were excluded if they had a history of chronic diseases, cervical cancer, a history of hysterectomy, or prior HPV vaccination.

Prospective participants were identified through door-to-

door survey. At enrollment participants were randomized to receive the HPV or control (Hepatitis-A) vaccine and were followed annually for 4 years, with high participation rates. At the completion of CVT in 2010, participants were individually unblinded and cross-over vaccination (XO visit) was offered. Participation in enrollment was 30.5% among invited women and 59.1% among eligible women. The study produced extensive information on vaccine efficacy and other aspects of HPV infection and associated conditions.

In addition, we compared selected demographic variables between study participants and women of the same age group and geographic area based on national census data. Compared with the census population, CVT participants had higher educational level, and a lower proportion were married, but the age distribution was very similar, with median ages of 21.0 years in the CVT cohort and 21.1 years in the census population [21].

At enrollment, a physician completed a medical history and physical exam that included measurement of weight and height.

At each visit, from enrollment (EV) through the 48-month follow-up visit (M48), a trained interviewer administered a risk factor interview. The questionnaire asked about years of education, marital status, income, household amenities, menstrual history, sexual, reproductive, and contraceptive history, and smoking status. Blood and cervical specimens were collected at each visit during CVT to evaluate the main objectives of the trial.

After the blinded phase of the study was completed, crossover vaccination was offered. At the first cross-over (XO) visit, the study doctor measured weight. No risk factor questionnaire was administered at the XO visit (Supplementary Figure 1). Therefore, the M48 data were used as the best available approximation of participants' status at the time of XO. Indeed, the M48 questionnaire represents the closest available risk-factor assessment, with a mean interval of only 1.1 years between M48 and XO. Given this short gap and the relative stability of the risk-factor variables collected in our adult cohort, using M48 responses allows us to reasonably infer participants' risk profiles at the time of XO.

Figure 1. CONSORT diagram. Prevalence and determinants of overweight, obesity and weight gain among Young Women in Costa Rica




Figure 1: Consort Diagram

Figure 1 presents the CONSORT diagram illustrating participant inclusion across the study. A total of 7,465 women were enrolled in the Costa Rica HPV Vaccine Trial (CVT) and included in the prevalence analysis at enrollment. At the cross-over visit, 2,025 participants did not attend. Among those who attended ($n = 5,440$), 264 were excluded due to missing Month-48 questionnaires ($n = 249$) or missing anthropometric measures ($n = 15$), yielding a final analytical sample of 5,176 women.

The prevalence of overweight/obesity was estimated at enrollment (2004–2005) among the 7,465 women and at follow-up (2010–2011) among the 5,176 women who completed the visit, who were also included in the weight gain analysis.

Outcomes

Weight and height were used to calculate body mass index (BMI) at enrollment (2004–2005). At cross over visit (2010–2011), weight was measured, but not height. Given the participant's age at enrollment (over 18 years), no change in height was expected between enrollment and XO visit. BMI was used to classify participants as underweight (< 18.5), normal weight (18.5–24.9), overweight (25.0–29.9) or obesity ($\text{BMI} \geq 30$).

Weight gain was defined by comparing weight at XO and at enrollment. For the analysis, we used a dichotomic indicator describing a relative weight increase $\geq 20\%$ from enrollment to the XO visit. A similar analysis was conducted using a dichotomic indicator describing an absolute weight gain $\geq 10\text{kg}$.

Independent Variables

For the prevalence analysis, we used sociodemographic, behavioral, hormonal, and reproductive covariates as independent variables strongly associated with BMI previous literature review. Regions were classified into three categories according to their prevalence of overweight/obesity: low ($< 25\%$), medium (25% to $< 35\%$), and high ($\geq 35\%$).

For the weight gain analysis, we also added time-dependent covariates, including marital status (separation, marriage), menstrual cycle regularity, and reproductive behaviors (number of spontaneous abortions/pregnancies during follow-up, change in contraceptive use). The information from the interviews applied at enrollment and at the 48-month follow-up

visit of CVT was used, since at the XO visit the risk factor questionnaire was not applied.

Statistical Analysis

Association between Age and Overweight/Obesity

The crude association between age and overweight/obesity prevalence was analyzed using both enrollment and cross-over visits. We tested non-linearity associations between age and overweight/obesity prevalence by testing the existence of significant joinpoints [23].

To avoid selection bias, we also impute BMI categories for the 2,289 participants who were not included in follow-up analysis, as a sensitivity analysis. Imputation was based on BMI at enrollment, age and socioeconomic characteristics (including educational level, marital status and age at menarche).

Incidence Rates

We calculated the follow-up incidence rates of overweight and obesity. We also estimated the annual incidence rates of overweight and obesity as the annual risk of developing these conditions, assuming a constant rate of change over the period. The rates were estimated by dividing the number of incident cases of overweight or obesity between enrollment and XO by the total number of person-years of follow-up among participants without overweight or obesity at enrollment.

Determinants of Overweight/Obesity

The analysis of the determinants of overweight/obesity at enrollment included 7,465 women who participated in the enrollment visit. We used a fully adjusted logistic regression model using all the independent variables measured at enrollment. We analyzed the determinants of obesity at enrollment; and the determinants of overweight/obesity at the follow-up visit as complementary analysis.

The analysis of the determinants of weight gain over five years included the 5,176 women who participated in the enrollment and the cross-over visits. We used a fully adjusted logistic regression model using all the independent variables measured at enrollment and at M48.

All statistical analyses were conducted using Stata software version 18.

Results

Table 1 shows the general characteristics of the study participants at both time points (2004–2005 and 2010–2011). Women were between 18 and 25 years old at enrollment and between 22 and 32 years at the follow-up visit (FW). 40% were married at enrollment and 60% at the follow-up visit. The fraction of nulliparous women decreased from 52% at recruitment to 29% at the follow-up visit. At enrollment, most women had used hormonal contraception and 7.9% were current smokers. At enrollment, 28.2% of women had completed pri-

mary education, compared with 29.5% at follow-up. Similarly, 59.4% of women resided in cantons with high prevalence of overweight and obesity at enrollment, and 59.2% did so at follow-up. Regarding early menarche, 7.5% reported having had their first menstrual period at age 10 years or younger at enrollment, compared with 7.8% at follow-up. These findings indicate that the distribution of education level, canton of residence, and age at menarche remained essentially unchanged throughout the study period, suggesting the absence of selection bias among the subset of the study population who participated in the follow-up visits included in this analysis.

Table 1: Sociodemographic and Behavior Characteristics of Women Aged 18-25. Guanacaste, Puntarenas, Costa Rica, 2004-2005 and 2010-2011.

Characteristics	2004-2005 Ages 18-25 (N=7465)		2010-2011 Ages 22-32 (N=5176)	
	n	%	n	%
Age				
18-19	2437	32.6		
20-21	1852	24.8		
22-23	1663	22.3	1188	23.0
24-25	1513	20.3	1371	26.5
26-27			1191	23.0
28-29			1122	21.7
30-32			304	5.9
Marital status				
Married/Cohabiting	3076	41.2	3167	61.5
Single/Divorced/Separated/Widowed	4381	58.8	1987	38.5
No information	8		22	
Education Level				
Primary	2096	28.2	1521	29.5
Lower Secondary	1697	22.8	1179	22.9
Upper Secondary	2246	30.2	1543	29.9
University	1396	18.8	910	17.7
No information	30		23	
Prevalence overweight/obesity by cantons				
Low	573	7.7	415	8.0
Middle	2461	33	1696	32.8
High	4431	59.4	3065	59.2
Smoking History				
Non-Smoker	6440	86.4	4168	80.9
Ever Smoked	427	5.7	655	12.7
Currently Smokes	590	7.9	331	6.4

No information	8		22	
Menarche				
≥14years	1472	19.8	1012	19.6
13 years	1812	24.3	1239	23.9
12 years	2315	31.1	1604	31
11 years	1293	17.4	906	17.5
≤ 10 years	560	7.5	405	7.8
No information	13		10	
Menstrual Cycle Regularity				
Regular	4853	65.2	3803	75.7
Irregular	2588	34.8	1218	24.3
No information	24		155	
Number of Pregnancies (Live Births)				
Nulliparous	3907	52.3	1478	28.6
1	2192	29.4	1654	32.0
2	952	12.8	1274	24.6
≥3	414	5.5	770	14.9
History of Abortions				
None	6933	92.9	4540	87.7
≥1	527	7.1	636	12.3
No information	5		0	
Use of Oral Contraceptives				
Never used	2942	39.5	927	18.2
Used in the pass	1374	18.5	2189	43.0
Currently using	3125	42	1980	38.9
No information	24		80	
Use of Injectable Contraceptives				
Never used	5069	68.6	2426	47.7
Used in the past	1876	25.4	2044	40.2
Currently using	447	6	619	12.2
No information	73		87	

Table 2: BMI distribution of CVT participants at enrollment and follow-up

BMI Category	2004-2005 (n = 7,465)	%	2010-2011 (n=5,176)	%	Cumulative Incidence over Follow-up %	Estimated Annual Incidence %
Underweight	556	7.5	160	3.1	-	-
Normal Weight	4306	57.7	2120	41.0	-	-
Overweight	1658	22.1	1585	30.6	-	-
Obesity I	603	8.1	785	15.2	-	-

Obesity II	228	3.1	327	6.3	-	-
Obesity III	114	1.5	199	3.8	-	-
Obesity (all categories combined)	945	12.7	1311	25.3	14.8	2.8
Overweight/Obesity (all categories combined)	2603	34.9	2896	56.0	33.1	7.0

The prevalence of overweight/obesity at enrollment (2004–2005) was 35% and increased at follow-up (2010–2011) to 56% (Table 2). Among the participants who attended follow-up visit, the prevalence of overweight/obesity at enrolment was similar (37%) (Supplementary Table 1). In addition, the analysis including imputation of missing BMIs produced very similar results (54.7% of overweight/obesity at the follow-up visit), confirming the absence of selection bias (Supplementary Table 1).

The cumulative incidence of overweight/obesity during follow-up was 33.1%, and the cumulative incidence of obesity during follow-up was 14.8%. The annualized incidence of overweight/obesity was 7.0%, and the annualized incidence of obesity was 2.8% (Supplementary Table 1). Participants were classified into three weight change categories during follow-up: weight loss (16.0%), weight maintenance (1.4%), and any weight gain (82.6%) (Supplementary Table 2). 19% experienced a $\geq 20\%$ BMI increase and 26% had an absolute weight gain of at least 10 kg. These patterns indicate a general shift to-

ward higher BMI categories over the study period.

Figure 2 shows the percentage of overweight/obesity by age. It illustrates the significant increase in overweight/obesity rates with age. The percentage of overweight/obesity is below 25% at 18 years old and above 70% at 31 years old. Percentages of overweight/obesity are similar in the EV and follow-up visits among the overlapping age groups (23–25.5 years old) ($p=0.52$), suggesting the absence of a secular trend during the study period. In absence of significant joinpoint, the association between age and the prevalence of overweight/obesity can be described as linear.

Supplementary Figure 2 shows the prevalence of overweight and obesity at enrollment by region/canton of residence, revealing significant geographic differences ($p<0.01$). Prevalence ranged from approximately 23% in the lowest-prevalence areas (Montes de Oro and Tilarán) to around 40% in the highest-prevalence areas (Puntarenas, La Cruz, Hojanca and Liberia).




Figure 2: Representation of the percentage of overweight/obesity in relation to age for both studies:

Table 3: Multivariate model of determinants of overweight and obesity at EV (2004-2005) of Women Aged 18-25

Characteristics	Overweight/Obesity (%) (N=2603)	Full Multivariate Model
Age		Trend p<0.01
18-19	25.3	1
20-21	31.9	1.2 [1.1 - 1.4]
22-23	38.8	1.4 [1.2 - 1.7]
24-25	49.6	2.1 [1.8 - 2.5]
Marital Status		
Married/Cohabiting	45.7	1
Single/Divorced/Widowed	27.3	0.7 [0.6 - 0.8]
Education Level		Trend p<0.01
University	25.9	1
Upper Secondary	27.6	1.1 [0.9 - 1.3]
Lower Secondary	37.7	1.5 [1.2 - 1.8]
Primary	46.3	1.8 [1.6 - 2.2]
Prevalence overweight/obesity by cantons		Trend p<0.01
Low	23.7	1
Middle	32.7	1.4 [1.1 - 1.8]
High	37.5	1.7 [1.4 - 2.1]
Smoking History		Trend p=0.04
Non-Smoker	34.4	1
Ever Smoked	37.2	1.3 [1.0 - 1.6]
Currently Smokes	38.3	1.3 [1.1 - 1.6]
Menarche		Trend p<0.01
≥ 14 years	25.0	1
13 years	29.5	1.3 [1.1 - 1.6]
12 years	36.8	2.0 [1.7 - 2.3]
11 years	42.0	2.4 [2.1 - 2.9]
≤ 10 years	54.6	4.3 [3.4 - 5.3]
Menstrual Cycle Regularity		
Regular	34.6	1
Irregular	35.6	1.2 [1.1 - 1.4]
Number of Pregnancies (Live Births)		Trend p<0.01
Nulliparous	25.5	1
1	40.2	1.2 [1.0 - 1.4]
2	50.8	1.3 [1.1 - 1.6]
≥3	58.5	1.4 [1.1 - 1.9]
History of Abortions		

None	33.8	1
≥1	48.4	1.1 [0.9 - 1.3]
Use of oral contraceptives		Trend p=0.81
Never used	26.6	1
Used in the past	42.5	1.2 [1.0 - 1.4]
Currently using	39.3	1.0 [0.9 - 1.2]
Use of injectable contraceptives		Trend p=0.38
Never used	30.0	1
Used in the past	47.6	1.2 [1.1 - 1.4]
Currently using	36.7	0.9 [0.7 - 1.1]

Bolded Odds ratio indicates significant associations at 5% level.

Full Multivariate model is adjusted for all variables listed in the table.

Table 3 presents the multivariate model of determinants of overweight and obesity at enrollment (2004-2005). It confirms that overweight and obesity significantly increase with age (p-trend<0.01). Single/divorced/widowed women had a lower risk of having overweight/obesity, compared to married women or those in cohabitation (OR = 0.7 [0.6-0.8]). Women with primary level education had a higher risk of having overweight/obesity (OR = 1.8 [1.6-2.2]) compared to those with university level education. The differences across regions still appeared in the fully adjusted model and are therefore not explained by the model's variables. In our population of young adult women, smoking, whether current or past, increased the risk of being overweight and obesity compared to those who had never smoked (OR = 1.3 [1.1-1.6]).

Having an early menarche (≤ 10 years) increases the risk of overweight/obesity compared to those who had late menarche (≥ 14 years) (OR = 4.3 [3.4-5.3], p-trend <0.01). Women who had irregular menstrual periods had a higher risk of having overweight/obesity, compared to women who had reg-

ular menstrual cycles (OR = 1.2 [1.1-1.4]). The risk of having overweight/obesity also increased with the number of pregnancies (p-trend<0.01). Women who had ever used injectable contraceptives in the past had a higher risk of having overweight/obesity compared to women who had never used injectable contraceptives (OR = 1.2 [1.1-1.4]), but women who were currently using oral contraceptives did not show higher risk of having overweight/obesity (OR = 0.9 [0.7-1.1]).

The determinants of obesity alone were very similar to the determinants of overweight/obesity (Supplementary Table 3), except that the number of pregnancies was not a significant determinant of obesity. The analysis of determinants of overweight/obesity based on the follow-up visit confirmed the association between overweight/obesity and age, marital status, education level, age at menarche, and regularity of menstrual cycles. At the follow-up visit, overweight/obesity was associated with oral contraceptive, but not with injectable contraception, in opposition to EV visit results (Supplementary Table 4).

Table 4: Multivariate model of determinants of weight gain between 2004–2005 and 2010–2011. Based on a 20%+ Increase in BMI. Guanacaste, Puntarenas, Costa Rica, 2004-2005 and 2010-2011.

Characteristics	$\Delta \geq 20\%$ (N=977)	Full Multivariate Model
BMI EV		Trend p<0.01
Underweight	25.1	1.3 [1.0 - 1.8]
Normal weight	20.3	1
Overweight	18.3	0.9 [0.8 - 1.1]
Obesity	10.6	0.5 [0.4 - 0.7]
Age at EV		Trend p=0.23

18-19	22.1	1
20-21	20.2	1.0 [0.9 - 1.3]
22-23	16.6	0.9 [0.7 - 1.1]
24-25	15.0	0.9 [0.7 - 1.2]
Marital Status EV		
Married/Cohabiting	15.1	1
Single/Divorced/Widowed	21.8	1.0 [0.8 - 1.3]
Marital status at M48		Trend p<0.01
Without changes in marital status	15.7	1
Separation between EV and M48	13.9	0.9 [0.6 - 1.2]
Married between EV and M48	29.2	1.8 [1.5 - 2.2]
Education Level EV		Trend p=0.24
University	20.0	1
Upper Secondary	20.2	1.0 [0.8 - 1.3]
Lower Secondary	18.8	1.1 [0.9 - 1.4]
Primary	16.8	1.1 [0.8 - 1.4]
Prevalence overweight/obesity by cantons		Trend p=0.08
Low	23.1	1
Middle	20.8	0.9 [0.7 - 1.2]
High	17.3	0.8 [0.6 - 1.0]
Smoking History		Trend p=0.14
Non-Smoker	18.3	1
Ever Smoked	22.6	1.2 [0.9 - 1.5]
Currently Smokes	19.3	1.1 [0.8 - 1.5]
Menarche EV		Trend p<0.01
≥ 14 years	15.5	1
13 years	17.8	1.3 [1.0 - 1.7]
12 years	20.4	1.6 [1.3 - 2.0]
11 years	20.9	1.7 [1.3 - 2.1]
≤ 10 years	20.7	1.9 [1.4 - 2.6]
Menstrual Cycle Regularity EV		
Regular	19.0	1
Irregular	18.7	1.2 [0.9 - 1.6]
Menstrual Cycle Regularity M48		Trend p=0.56
Without changes in menstrual cycle	18.5	1
Regular at M48	21.5	0.8 [0.6 - 1.0]
Irregular at M48	19.2	1.2 [1.0 - 1.5]
Number of pregnancies EV		Trend p=0.10
Nulliparous	21.9	1

1	16.7	0.6 [0.5 - 0.8]
≥2	14.7	0.6 [0.4 - 0.8]
Number of pregnancies between EV and M48		Trend p=0.02
Nulliparous	17.7	1
1	20.2	1.3 [1.1 - 1.7]
≥2	17.1	1.5 [1.1 - 2.1]
History of Abortions EV		
None	19.0	1
≥1	16.9	1.4 [0.9 - 2.3]
Abortions between EV and M48		
None	19.1	1
≥1	17.5	0.7 [0.5 - 1.0]
Use of Oral contraceptives M48		Trend p<0.01
Never used	15.0	1
Used in the past	19.1	1.4 [1.1 - 1.7]
Currently using	20.5	1.6 [1.2 - 2.0]
Use of Injectable contraceptives M48		Trend p=0.17
Never used	18.4	1
Used in the past	18.3	1.0 [0.9 - 1.2]
Currently using	22.6	1.2 [0.9 - 1.5]

Bolded Odds ratio indicates significant associations at 5% level EV (enrollment visit). M48 (4-year visit) Full Multivariate model is adjusted for all variables listed in the table.

Table 4 presents the determinants of weight gain between 2004–2005 and 2010–2011, defined as a $\geq 20\%$ increase in BMI. A total of 977 participants (19%) experienced a $\geq 20\%$ increase in BMI. Women who reported having married between EV and M48 (OR = 1.8 [1.5–2.2]), who had early menarche (OR = 1.9 [1.4–2.6]), who were pregnant during the period (OR = 1.5 [1.1–2.1]) and who use oral contraceptives (OR = 1.6 [1.2–2.0]) had a higher probability of $\geq 20\%$ -weight gain in the multivariate model. Also, in the fully adjusted model, having been pregnant before the period studied was associated with a lower likelihood of $\geq 20\%$ -weight gain (OR = 0.6 [0.4–0.8]).

The results from both the relative weight gain model ($\geq 20\%$) and the absolute weight gain model ($\geq 10\text{kg}$) were very similar, suggesting consistent associations across both approaches (Supplementary Table 5).

Discussion

In this cohort of 18–25 years old women from Costa Rica, we observed a significant increase in the prevalence of overweight and obesity over five years of follow-up, from 35% at enrollment to 56%. The annual incidence rates were 7.0% for overweight and 2.8% for obesity. Overweight/obesity was associated with older age, lower educational level, early menarche, irregular menstrual periods, pregnancies, past use of injectable contraceptives and smoking history. Being single was associated with a lower risk of overweight and obesity.

Although comparable national data are not available for Costa Rica, international evidence suggests that obesity has increased with earlier onset and greater severity, raising concerns about long-term health consequences beginning in childhood [24, 25].

Older age was also associated with higher prevalence of overweight and obesity in our cohort. Previous research has shown that women between the ages of 18 and 35 experience the most rapid weight gain, with a progressive increase in

BMI up to age 35 [26]. This period typically involves hormonal stabilization following adolescence and the onset of important lifestyle changes such as entering the workforce, forming relationships, and reduced engagement in physical activity [16, 26].

Lower educational attainment was another significant predictor of overweight and obesity. Our findings align with prior studies in Costa Rica and other settings, where women with only primary education were more likely to have obesity [27–29]. Education is often correlated with higher socioeconomic status, greater health literacy, and better access to health-promoting resources [16]. However, some studies conducted in Costa Rica have reported no significant differences in anthropometric indicators by education level among adult women [19]. Interestingly, Costa Rican data also show that in childhood, overweight and obesity are more prevalent among those from higher socioeconomic backgrounds, suggesting a possible reversal of the social gradient during the transition to adulthood [30]. An interesting finding of this study is that early menarche (≤ 10 years) was significantly associated with overweight and obesity. This result is consistent with several previous studies showing that early pubertal timing is linked to greater adiposity, higher BMI, and increased waist circumference throughout adulthood [31–34]. The association may be partly explained by early activation of estrogen and gonadotropin-releasing hormone secretion, which can be triggered by elevated BMI in childhood [35]. However, even after adjusting for childhood BMI, early menarche has been associated with higher adult BMI, suggesting an independent contribution to weight outcomes [36].

Other factors associated with overweight, and obesity included irregular menstrual cycles, recent pregnancies, past use of injectable contraceptives and smoking history. Also, being single was associated with lower likelihood of having overweight or obesity. These associations are consistent with findings from other populations. Menstrual irregularity has been linked to anovulation and excess weight [37]. Pregnancies during follow-up were linked to weight gain, while pregnancies prior to enrollment were not, suggesting that recent pregnancies contributed more strongly to incident overweight and obesity, in line with literature on postpartum weight retention [38, 39]. Past use of injectable contraceptives was also associated with overweight and obesity at enrollment, consistent with studies reporting weight gain linked to hormonal

contraceptive use [40–42]. Smoking has been associated with altered eating behavior and weight regulation [43]. Single women were associated with a lower risk of overweight and obesity compared to married women. Women may maintain less healthy eating patterns after entering marriage or cohabitation, regardless of whether they have children [29]. Marriage during follow-up was associated with greater weight gain compared to single women, as previously reported in longitudinal studies that observed increased BMI after entering marriage or cohabitation [26, 44, 45].

We also observed geographic differences in overweight and obesity, with higher prevalence in coastal regions (e.g., Puntarenas, La Cruz) and lower prevalence in mountainous regions (e.g., Montes de Oro, Tilarán). These differences were not explained by the variables included in our models and may relate to population composition or regional environmental factors, as previously described in Costa Rican studies [46–49].

This study, based on a large, population-based trial of young Costa Rican women followed over five years, provides strong evidence of rising overweight and obesity during young adulthood. Its strengths include the large sample size, long follow-up, and consideration of sociodemographic, behavioral, hormonal, and reproductive factors. These findings highlight education, regional disparities, and early-life determinants as critical targets for prevention.

However, limitations include reliance on BMI (which cannot distinguish fat from lean mass), lack of data on diet and physical activity, and restricted generalizability due to study population characteristics and inclusion/exclusion criteria. Given that the CVT sample had a higher level of education than the national census population and considering that the data were collected nearly two decades ago, the reported prevalence of overweight and obesity is likely underestimated and may not fully reflect current population prevalence. Nevertheless, these limitations do not affect the analysis of determinants or the study of weight gain.

Overall, the study demonstrates a significant increase in weight during young adulthood, driven by a complex interplay of sociodemographic, reproductive, behavioral, and regional factors. These patterns highlight the need for more geographically tailored interventions and suggest that hormonal and reproductive determinants merit further investigation.

Broader analyses of obesity incidence in women and in the general Costa Rican population would also help contextualize these findings and guide future prevention strategies.

Importantly, these results carry substantial implications for public health policy. Women in this age range are at high risk for developing obesity and related complications, often even before clinical manifestations become evident. This makes early adulthood a critical window for prevention. Our findings underscore the need for targeted interventions such as age-specific obesity screening and postpartum programs to help mitigate long-term weight gain among young women.

Acknowledgements

We are grateful to all the young women of Costa Rica who participated in the CVT study, who gave of themselves in participating in this effort. In Costa Rica, we acknowledge the tremendous effort and dedication of the staff involved in this project; we would like to specifically acknowledge the meaningful contributions by Carlos Avila, Loretto Carvajal, Rebeca Ocampo, Cristian Montero, Diego Guillen and Mario Alfaro. In the United States, we extend our appreciation to the team from Information Management Services (IMS) responsible for the development and maintenance of the data system used in the trial and who serve as the data management center for this effort, especially Jean Cyr, Julie Buckland, John Schussler, and Brian Befano. We thank Dr. Diane Solomon (CVT: medical monitor & QC pathologist) for her invaluable contributions in the design and conduct of the trial and Nora Macklin (CVT) and Kate Torres (LFU) for the expertise in coordinating the study. We thank the members of the Data and Safety Monitoring Board charged with protecting the safety and interest of participants during the randomized, blinded phase of our study (Steve Self, Chair, Adriana Benavides, Ruth Karron, Ritu Nayar, and Nancy Roach) and members of the external Scientific HPV Working Group who have contributed to the success of our efforts over the years (Gypsyamber D'Souza, Chair, Ruanne Barnabas, Karla Chavez, Diane Davey, Michelle Khan, Silvia Lara, Henriette Raventós, Wasima Rida, Richard Roden, Maria del Rocío Sáenz Madrigal, and Margaret Stanley). We thank all the people who worked with a lot of energy and enthusiasm on the original project. ACIB--FUNIN dedicates this study to the memory of our beloved colleague and friend Dr. Paula González Maya, a distinguished researcher in the field of cervical cancer prevention. Dr.

González Maya also recognized the importance of addressing emerging public health challenges in cancer prevention and control, including her early suggestion to study the growing epidemic of obesity. Her advice and support are gratefully acknowledged. She passed away on March 26, 2020.

Conflict of Interest Statement

The Costa Rica HPV Vaccine Trial is a long-standing collaboration between investigators in Costa Rica and the NCI. The trial is sponsored and funded by the NCI (contract N01-CP-11005), with funding support from the National Institutes of Health Office of Research on Women's Health. Glaxo-SmithKline Biologicals (GSK) provided vaccine and support for aspects of the trial associated with regulatory submission needs of the company under a Clinical Trials Agreement (FDA BB-IND 7920) during the four-year, randomized blinded phase of our study. The NCI and Costa Rica investigators are responsible for the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation of the manuscript. Registered with ClinicalTrials.gov NCT00128661. The authors declare no conflict of interest.

Data Availability

Participant data can be shared with outside collaborators for research to understand more about the performance of the HPV vaccine, immune response to the vaccine, and broader study factors associated with the natural history of HPV infection and risk factors for infection and disease. Outside collaborators can apply to access our protocols and data from the blinded phase of the Costa Rica Vaccine Trial (NCT00128661). For the trial summary, current publications, and contact information for data access see: <https://dceg.cancer.gov/research/who-we-study/cohorts/costa-rica-vaccine-trial>.

The Costa Rica HPV Vaccine Trial Group:

Bernal Cortés¹; Paula González^{1,10}; Rolando Herrero¹; Carolina Porras¹; Allan Hildesheim²; Aimée R. Kreimer², Douglas R. Lowy²; Mark Schiffman², John T Schiller², Sholom Wacholder^{2,10}, Ligia A Pinto³; Troy J Kemp³; Mary K. Sidawy⁴; Wim Quint^{5,10}; Leen-Jan van Doorn⁵; Linda Struijk⁵; Joel M Palefsky⁶; Teresa M Darragh⁶; Mark H Stoler⁷; Ana Ce-

5. DDL Diagnostic Laboratory, Netherlands

6. University of California, San Francisco, CA, USA



7. Emeritus, University of Virginia, Charlottesville, VA, USA

8. Independent Consultant, San José, Costa Rica

9. Mayo Clinic, Jacksonville, FL, USA

10. Deceased

Supplementary Information



Supplementary Table 1: BMI distribution of CVT participants at enrollment and follow-up including imputation of missing BMIs.

BMI Category	2004-2005 (n = 7,465)	%	2004-2005 In those who did follow-up visit (n=5,176)	%	2010-2011 (n=5,176)	%	2010-2011 with imputation (%)	Cumulative Incidence over Follow-up %	Estimated Annual Incidence %
Underweight	556	7.5	379	7.3	160	3.1	3.1	-	-
Normal Weight	4306	57.7	2902	56.1	2120	41	42.1	-	-
Overweight	1658	22.1	1181	22.8	1585	30.6	30.7	-	-
Obesity I	603	8.1	448	8.7	785	15.2	14.6	-	-
Obesity II	228	3.1	173	3.3	327	6.3	5.0	-	-
Obesity III	114	1.5	93	1.8	199	3.8	4.4	-	-
Obesity (all categories combined)	945	12.7	714	13.8	1311	25.3	24.1	14.8	2.8
Overweight/Obesity (all categories combined)	2603	34.9	1895	36.6	2896	56	54.7	33.1	7.0

Supplementary Table 2: Distribution of Weight Change Categories during Follow-up

Weight Change Category	(N)	%	Cum (%)
Weight Loss	826	15.96%	15.96%
Weight Maintenance	73	1.4%	17.37%
Weight gain	4277	82.63%	100%
Total	5176	100%	

Supplementary Table 3: Multivariate model of determinants of obesity at EV (2004-2005) of Women Aged 18-25.

Characteristics	Obesity (%) (N=945)	Full Multivariate Model
Age		Trend p<0.01
18-19	8.8	1
20-21	11.1	1.2 [1.0 - 1.5]
22-23	14.7	1.5 [1.2 - 1.9]
24-25	18.6	2.0 [1.6 - 2.5]
Marital Status		
Married/Cohabiting	17	1
Single/Divorced/Widowed	9.6	0.7 [0.6 - 0.9]
Education Level		Trend p<0.01
University	8.2	1

Upper Secondary	9.6	1.2 [1.0 - 1.6]
Lower Secondary	13.3	1.5 [1.2 - 2.0]
Primary	18.4	2.1 [1.6 - 2.7]
Prevalence overweight/obesity by cantons		Trend p<0.01
Low	7.5	1
Middle	11.4	1.5 [1.0 - 2.1]
High	14	1.8 [1.3 - 2.5]
Smoking History		Trend p<0.01
Non-Smoker	12.2	1
Ever Smoked	15.5	1.6 [1.2 - 2.1]
Currently Smokes	16.1	1.6 [1.2 - 2.0]
Menarche		Trend p<0.01
≥ 14 years	7.3	1
13 years	10.2	1.5 [1.2 - 2.0]
12 years	13	2.1 [1.6 - 2.6]
11 years	17.4	3.0 [2.3 - 3.8]
≤ 10 years	23	4.3 [3.2 - 5.7]
Menstrual Cycle Regularity		
Regular	11.8	1
Irregular	14.3	1.4 [1.2 - 1.7]
Number of Pregnancies (Live Births)		Trend p=0.92
Nulliparous	9	1
1	14.7	1.1 [0.8 - 1.3]
2	19	1.0 [0.8 - 1.4]
≥3	22	1.0 [0.7 - 1.4]
History of Abortions		
None	12.3	1
≥1	17.5	1.0 [0.8 - 1.4]
Use of oral contraceptives		Trend p=0.72
Never used	9.6	1
Used in the past	16.3	1.1 [0.9 - 1.4]
Currently using	13.9	1.0 [0.8 - 1.2]
Use of injectable contraceptives		Trend p=0.48
Never used	10.5	1
Used in the past	18.5	1.3 [1.1 - 1.6]
Currently using	12.3	0.8 [0.6 - 1.1]

Bolded Odds ratio indicates significant associations at 5% level.

Full Multivariate model is adjusted for all variables listed in the table

Supplementary Table 4: Multivariate model of determinants of overweight and obesity at M48 visit (2010-2011) of Women Aged 18-25.

Characteristics	Overweight/Obesity (2896) %	Full Multivariate Model
Age		Trend p = 0.000
22-23	45.8	1
24-25	52.6	1.3 [1.1 - 1.5]
26-27	56.9	1.4 [1.2 - 1.7]
28-29	65.7	2.0 [1.7 - 2.4]
30-32	71.1	2.5 [1.8 - 3.3]
Marital status		
Married/Cohabiting	61.3	1
Single/Divorced/Widowed	47.6	0.8 [0.7 - 0.9]
Education Level		Trend p = 0.000
University	46.4	0.6 [0.5 - 0.7]
Upper Secondary	49.6	0.7 [0.6 - 0.8]
Lower Secondary	59	0.9 [0.7 - 1.0]
Primary	65.6	1
Smoking History		
Non- Smoker	55.1	1
Ever Smoked	58.3	1.1 [0.9 - 1.3]
Currently Smokes	62.8	1.4 [1.1 - 1.8]
Menarche		Trend p = 0.000
≥ 15 years	45.5	0.3 [0.2 - 0.4]
14 years	43.9	0.3 [0.2 - 0.4]
13 years	51.3	0.4 [0.3 - 0.5]
12 years	57.3	0.5 [0.4 - 0.7]
11 years	66.1	0.8 [0.6 - 1.1]
≤ 10 years	71.4	1
Menstrual Cycle Regularity		
Regular	53.9	1
Irregular	61.9	1.4 [1.2 - 1.6]
Number of Pregnancies		Trend p = 0.097
Nulliparous	44	1
1	54.6	1.1 [0.9 - 1.3]
2	62.4	1.2 [0.9 - 1.4]
≥3	71	1.4 [1.0 - 1.8]
History of Abortions		Trend p=0.455
None	55	1

1	62.3	0.9 [0.7 - 1.1]
≥2	67.4	0.9 [0.6 - 1.5]
Use of oral contraceptives		Trend p=0.106
Never used	44.6	1
Used in the past	61.7	1.4 [1.2 - 1.7]
Currently using	55.1	1.3 [1.1 - 1.6]
Use of injectables contraceptives		Trend p=0.903
Never used	50.5	1
Used in the past	62.1	1.1 [1.0 - 1.3]
Currently using	56.5	0.9 [0.7 - 1.1]

Bolded Odds ratio indicates significant associations at 5% level.

Full Multivariate model is adjusted for all variables listed in the table.

Supplementary Table 5: Multivariate model of determinants of weight gain between 2004–2005 and 2010–2011. Based on a 10 kg absolute weight gain. Guanacaste, Puntarenas, Costa Rica, 2004-2005 and 2010-2011.

Characteristics	Gained 10K+ (1355)	Full Multivariate Model
BMI EV		Trend p<0.01
Underweight	19.3	0.8 [0.6 - 1.0]
Normal weight	23.7	1
Overweight	31.5	1.6 [1.3 - 1.8]
Obesity	31	1.6 [1.3 - 1.9]
Age EV		Trend p=0.33
18-19	27.8	1
20-21	27.7	1.1 [0.9 - 1.3]
22-23	24	0.9 [0.7 - 1.1]
24-25	24.3	1.1 [0.8 - 1.2]
Marital Status EV		
Married/Cohabiting	24.1	1
Single/Divorced/Widowed	27.8	0.9 [0.7 - 1.1]
Marital status at M48		Trend p<0.01
Without changes in marital status	22.8	1
Separation at M48	21.5	0.8 [0.6 - 1.1]
Married at M48	37.1	2.0 [1.7 - 2.4]
Education Level EV		Trend p=0.46
University	25.5	1
Upper Secondary	26.4	1.0 [0.8 - 1.2]

Lower Secondary	26.9	1.1 [0.9 - 1.3]
Primary	26	1.1 [0.8 - 1.3]
Prevalence of overweight/obesity by cantons		Trend p=0.083
Low	28.9	1
Middle	28.4	1.0 [0.8 - 1.3]
High	24.6	0.8 [0.6 - 1.0]
Smoking History		Trend p=0.02
Non-Smoker	25.2	1
Ever Smoked	31.2	1.2 [1.0 - 1.4]
Currently Smokes	29.3	1.3 [1.0 - 1.6]
Menarche EV		Trend p<0.01
≥ 14 years	21.7	1
13 years	24.5	1.2 [1.0 - 1.5]
12 years	26.7	1.3 [1.1 - 1.6]
11 years	30	1.5 [1.2 - 1.9]
≤ 10 years	32.4	1.7 [1.3 - 2.2]
Menstrual Cycle Regularity EV Regular	26.8	1
Irregular	25.1	1.1 [0.9 - 1.4]
Menstrual Cycle Regularity M48		Trend p=0.35
Without changes in menstrual cycle	26.3	1
Regular at M48	23.5	0.8 [0.6 - 1.0]
Irregular at M48	30.4	1.2 [1.0 - 1.4]
Number of pregnancies EV		Trend p=0.08
Nulliparous	27.4	1
1	25.9	0.7 [0.6 - 0.9]
≥2	23.5	0.6 [0.4 - 0.8]
Number of pregnancies between EV and M48		Trend p=0.15
Nulliparous	22.3	1
1	29.1	1.4 [1.1 - 1.7]
≥2	24.2	1.4 [1.1 - 1.9]
History of Abortions EV		
None	26.1	1
≥1	27.3	1.3 [0.9 - 1.9]
Abortions between EV and M48		
None	26	1
≥1	27.4	0.9 [0.6 - 1.2]
Use of Oral contraceptives M48		Trend p=0.007

Never used	20.8	1
Used in the past	27.4	1.2 [1.0 - 1.5]
Currently using	27.5	1.3 [1.1 - 1.7]
Use of injectable contraceptives M48		Trend p=0.36
Never used	24.3	1
Used in the past	27.1	1.1 [0.9 - 1.3]
Currently using	29.9	1.2 [0.9 - 1.4]

Bolded Odds ratio indicates significant associations at 5% level. EV (enrollment visit), M48 (4-year visit)

Full Multivariate model is adjusted for all variables listed in the table.

References

1. A Obesity and Cancer | CDC [Internet]. 2021 [cited 2022 Feb 8]. Available from: <https://www.cdc.gov/cancer/obesity/index.htm>

2. Saad RA, and Qutob HM (2022) The relationship between anemia and obesity. Expert Review of Hematology. 15: 911–26.

3. Zannolli R, Mohn A, Buoni S, Pietrobelli A, Messina M, Chiarelli F, et al. (2008) Telomere length and obesity. Acta Paediatrica. 97: 952–4.

4. Rinonapoli G, Pace V, Ruggiero C, Ceccarini P, Bisaccia M, Meccariello L, et al. (2021) Obesity and Bone: A Complex Relationship. International Journal of Molecular Sciences. 22: 13662.

5. Fariñas Guerrero F, López Gigoso RM (2021) Obesidad, inmunidad y vacunación. Vacunas. 22: 180–8.

6. Obesity and overweight [Internet]. [cited 2025 Mar 28]. Available from: <https://www.int/news-room-fact-sheets-detail-obesity-and-overweight>

7. Dee A, Kearns K, O'Neill C, Sharp L, Staines A, et al. (2014) The direct and indirect costs of both overweight and obesity: a systematic review. BMC Research Notes. 7: 242.

8. Burkhauser RV, Cawley J. Beyond BMI (2008) The value of more accurate measures of fatness and obesity in social sci-

ence research. Journal of Health Economics. 27: 519–29.

9. World Health Organization. Obesity and overweight [Internet]. 2024 [cited 2025 Jan 31]. Available from: <https://www.who.int/news-room/fact-sheets-detail-obesity-and-overweight>

10. FAO. Panorama regional de la seguridad alimentaria y nutricional - América Latina y el Caribe 2022 [Internet]. FAO; IFAD; PAHO; WFP; UNICEF; 2023 [cited 2024 Apr 22]. Available from: <http://www.fao.org/documents/card/es/c/cc3859es>

11. Global Nutrition Report | Country Nutrition Profiles - Global Nutrition Report [Internet]. 2022 [cited 2025 Jan 31]. Available from: <https://globalnutritionreport.org/resources/nutrition-profiles/>

12. Evans-Meza DR, Bonilla-Carrión R, Salvatierra-Durán DR, González-Picado L. SALUD EN PERSPECTIVA N 12 UNIVERSIDAD HISPANOAMERICANA UNIDAD DE INVESTIGACIÓN. ESCUELA DE MEDICINA. 2023;

13. Lanoye A, Brown KL, LaRose JG (2017) The Transition into Young Adulthood: A Critical Period for Weight Control. Curr Diab Rep. 17: 114.

14. Evenson KR, Aytur SA, Borodulin K (2009) Physical activity beliefs, barriers, and enablers among postpartum women. J Womens Health (Larchmt). 18: 1925–34.

15. Nelson MC, Kocos R, Lytle LA, Perry CL (2009) Unders-

- tanding the Perceived Determinants of Weight-related Behaviors in Late Adolescence: A Qualitative Analysis among College Youth. *Journal of Nutrition Education and Behavior*. 41: 287–92.
16. Lunn PD (2010) The sports and exercise life-course: A survival analysis of recall data from Ireland. *Social Science & Medicine*. 70: 711–9.
 17. Mazerolle SM, Eason CM, Pitney WA, Mueller MN (2015) Sex and Employment-Setting Differences in Work--Family Conflict in Athletic Training. *J Athl Train*. 50: 958–63.
 18. Bellew - Women and Girls in Sport, Active Recreation & Phys.pdf [Internet]. [cited 2025 Mar 31]. Available from: https://www.sport.nsw.gov.au/sites/default/files/2021-04/sprinter-omen_and_girls_participation_review_final.pdf
 19. Gómez Salas G, Quesada Quesada D, Monge Rojas R, Gómez Salas G, Quesada Quesada D, et al. (2020) Perfil antropométrico y prevalencia de sobrepeso y obesidad en la población urbana de Costa Rica entre los 20 y 65 años agrupados por sexo: resultados del Estudio Latino Americano de Nutrición y Salud. *Nutrición Hospitalaria*. 37: 534–42.
 20. Pabón CA, Hubley E, Spurrell G, Smoczyk M. OBESIDAD: Análisis de la prevalencia de obesidad y sobrepeso en una población de adultos con bajos ingresos en Costa Rica. CS [Internet]. 2021 Apr 16 [cited 2025 Mar 14]; 5(2). Available from: <http://revista.cien.ciaysa.lud.ac.cr/ojs/index.php/cien-ciaysalud/article/view/244>
 21. Herrero R, Hildesheim A, Rodríguez AC, Wacholder S, Bratti C, Solomon D, et al. (2008) Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. *Vaccine*. 26: 4795–808.
 22. Gonzalez P, Hildesheim A, Herrero R, Katki H, Wacholder S, Porras C, et al. (2015) Rationale and design of a Long Term Follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. *Vaccine*. 33: 2141–51.
 23. Joinpoint Regression Program [Internet]. [cited 2025 Sept 5]. Available from: <https://surveil.lancet.ncer.gov/joinpoint/>
 24. Ng M, Dai X, Cogen RM, Abdelmasseh M, Abdollahi A, Abdollahi A, et al. (2024) National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990–2021, and forecasts up to 2050. *The Lancet*. 404: 2278–98.
 25. Cunningham SA, Hardy ST, Jones R, Ng C, Kramer MR, Narayan KMV (2022) Changes in the Incidence of Childhood Obesity. *Pediatrics*. 150: e2021053708.
 26. Pegington M, French DP, Harvie MN (2020) Why young women gain weight: A narrative review of influencing factors and possible solutions. *Obesity Reviews*. 21: e13002.
 27. 2023 - Panorama regional de la seguridad alimentaria y nu.pdf [Internet]. [cited 2024 Apr 22]. Available from: <https://www.fao.org/3/cc3859es/cc3859es.pdf>
 28. HLPE_2017_Nutrition-and-food-systems [Internet]. [cited 2024 Apr 22]. Available from: https://www.fao.org/fileadmin/user_upload/hlpe/hlpe_documents/HLPE_S_and_R/HLPE_2017_Nutrition-and-food-systems_S_R-ES.pdf
 29. Montero-López M, Santamaría-Ulloa C, Bekelman T, Arias-Quesada J, et al. (2021) Determinantes sociales de la salud y prevalencia de sobrepeso-obesidad en mujeres urbanas, según nivel socioeconómico. *Hacia la Promoción de la Salud*. 26(2):192–207.
 30. Gamboa-Gamboa T, Fantin R, Cordoba J, Caravaca I, Gómez-Duarte I (2021) Relationship between childhood obesity and socio-economic status among primary school children in Costa Rica. *Public Health Nutr*. 24: 3825–33.
 31. Dreyfus J, Jacobs DR, Mueller N, Schreiner PJ, Moran A, Carnethon MR, et al. (2015) Age at menarche and cardiometabolic risk in adulthood: the Coronary Artery Risk Development in Young Adults Study. 167: 344–52.
 32. Żurawiecka M, Wronka I (2020) Association between age at menarche and body mass index, waist circumference, waist to hip ratio, and waist to height ratio in adult women. *Am J Hum Biol*. 21: e23523.
 33. Gemelli IFB, Farias E dos S, Souza OF (2016) Age at Menarche and Its Association with Excess Weight and Body Fat Percentage in Girls in the Southwestern Region of the Brazilian Amazon. *Journal of Pediatric and Adolescent Gynecology*.

- cology. 29: 482–8.
34. Rosenberg L, Palmer JR, Wise LA, Horton NJ, Kumanyika SK, Adams-Campbell LL (2003) A Prospective Study of the Effect of Childbearing on Weight Gain in African-American Women. *Obesity Research*. 11: 1526–35.
 35. Cho H, Han JW (2023) Obesity-Related Factors in Adult Women with Early Menarche. *Healthcare*. 11: 557.
 36. Gaml-Sørensen A, Brix N, Ernst A, Lunddorf LLH, Arah OA, Strandberg-Larsen K, et al. (2025) Pubertal timing and tempo and body mass index trajectories: investigating the confounding role of childhood body mass index. *American Journal of Epidemiology*. kwaf063.
 37. Brewer CJ, Balen AH (2010) The adverse effects of obesity on conception and implantation. *Reproduction*. 140: 347–64.
 38. Hollis JL, Crozier SR, Inskip HM, Cooper C, Godfrey KM, Harvey NC, et al. (2017) Modifiable risk factors of maternal postpartum weight retention: an analysis of their combined impact and potential opportunities for prevention. *Int J Obes*. 41: 1091–8.
 39. Endres Lk, Straub H, McKinney C, Plunkett B, Minkovitz Cs, Schetter Cd, et al. (2015) Postpartum Weight Retention Risk Factors and Relationship to Obesity at One Year. *Obstet Gynecol*. 125: 144–52.
 40. Simmons KB, Edelman AB (2016) Hormonal contraception and obesity. *Fertility and Sterility*. 106: 1282–8.
 41. Endalifer ML, Diress Alen G, Addisu A, Linger B (2020) The association between combined oral contraceptive use and overweight/obesity: a secondary data analysis of the 2016 Ethiopia Demographic and Health Survey. *BMJ Open*. 10: e039229.
 42. Metz L, Isacco L, Redman LM (2022) Effect of oral contraceptives on energy balance in women: A review of current knowledge and potential cellular mechanisms. *Metabolism*. 126: 154919.
 43. Ely AV, Wetherill RR (2023) Reward and inhibition in obesity and cigarette smoking: Neurobiological overlaps and clinical implications. *Physiol Behav*. 260: 114049.
 44. Liu J, Garstka MA, Chai Z, Chen Y, Lipkova V, Cooper ME, et al. (2021) Marriage contributes to higher obesity risk in China: findings from the China Health and Nutrition Survey. *Annals of Translational Medicine*. 9: 564–64.
 45. Jeffery RW, Rick AM (2002) Cross-Sectional and Longitudinal Associations between Body Mass Index and Marriage-Related Factors. *Obesity Research*. 10: 809–15.
 46. Wang Z, Hildesheim A, Wang SS, Herrero R, Gonzalez P, Burdette L, et al. (2010) Genetic Admixture and Population Substructure in Guanacaste Costa Rica. *PLOS ONE*. 5: e13336.
 47. Guevara-Villalobos D, Céspedes-Vindas C, Flores-Soto N, Úbeda-Carrasquilla L, et al. (2019) Hábitos alimentarios de la población urbana costarricense. *Acta Médica Costarricense*. 61: 152–9.
 48. Gómez Salas G, Quesada D, Chinnock A (2020) Consumo de frutas y vegetales en la población urbana costarricense: Resultados del Estudio Latino Americano de Nutrición y Salud (ELANS)-Costa Rica. *Población y Salud en Mesoamérica*. 18: 450–70.
 49. Índice-de-Desarrollo-Humano-Cantonal-y-su-Ajustes--por-el-PIB-Ajuste-datos-al-2023.pdf [Internet]. [cited 2025 Mar 12]. Available from: <https://ci-odd.ucr.ac.cr/wp-content/uploads/2023/09/Índice-de-Desarrollo-Humano-Cantonal-y-su-Ajustes-por-el-PIB-Ajuste-datos-al-2023.pdf>